Effective does of Remimazolam toluenesulfate combine with Nalbuphine to inhibit body movement in abortion operation

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072384

Enrollment

Unknown

Registered

2023-06-12

Start date

2023-05-02

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Termination of pregnancy

Interventions

Group Remimazolam:Intravenous Remimazolam,when the patient sleep ,Ramsay 5 points and OAA/S 1 level.then start the operation.If respiratory inhibition, we can intravenous flumazenil ,the patien can w

Eligibility

Sex/Gender

All

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: The patients who planned to undergo painless abortion were selected , Age 18~45 years old ,BMI 20~25 kg /m2,ASA?~?.

Exclusion criteria

Exclusion criteria: SBP=160 mmHg,DBP=110 mmHg,HR=120bpm. A record of allergy to benzodiazepines , the patients with myasthenia gravis , a record of nervous systerm disease or inability to communicate.The operation took over 5 minutes.

Design outcomes

Primary

Measure	Time frame
The dosage of remazolam;	—

Secondary

Measure	Time frame
oxyhemoglobin saturation;awake time;untoward effect;	—

Countries

China

Contacts

Public ContactMai Ying

Shunde Hospital Affiliated to Jinan University

61304449@qq.com+86 137 0261 6858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026